On Wednesday, H.C. Wainwright maintained a Buy rating on Shattuck Labs (NASDAQ: STTK) stock with a price target of $16.00. The firm highlighted the resilience of Shattuck's SL-172154 in the face of challenges affecting the CD47 pathway.
The backdrop includes the European Hematology Association (EHA) 2024 conference held in June, where Gilead Sciences (NASDAQ:GILD) reported the discontinuation of magrolimab following its failure in trials for TP53 mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
This event created a significant negative impact on Shattuck's stock, despite the company presenting positive Phase 1b clinical updates for its HR-MDS/TP53 AML CD47 programs.
Investor confidence in the CD47 pathway has been low, contributing to the stock's depressed state. However, H.C. Wainwright sees potential for recovery, citing Shattuck's ability to navigate the "choppy waters."
The firm's stance is also informed by recent data from ALX Oncology, which reported results from its Phase 2 ASPEN-06 trial evaluating evorpacept in combination with other cancer treatments. Although the data was compelling, it was met with wariness from investors due to the general skepticism surrounding CD47-targeting therapies.
H.C. Wainwright's reiteration of the Buy rating and price target is based on their belief in Shattuck's prospects despite the broader market's caution regarding CD47 therapies. The firm's analyst commented on the need to recap and reiterate their stance, emphasizing the positive clinical updates from Shattuck and the potential for the stock to overcome the initial reactions to the negative news from the EHA conference.
The firm's recommendation remains unchanged, with a focus on the strengths of Shattuck's SL-172154 and its clinical progress. The $16.00 price target reflects H.C. Wainwright's confidence in the value of Shattuck Labs' shares amidst the ongoing challenges and investor sentiment in the CD47 therapeutic space.
In other recent news, Shattuck Labs has been making significant strides in its research and development activities. The company's therapeutic candidate SL-172154, currently under evaluation in multiple Phase 1 trials, received an orphan drug designation from the U.S. Food and Drug Administration (FDA), a status expected to speed up the drug's development.
Additionally, Shattuck Labs reported encouraging interim data from a Phase 1B trial for SL-172154, indicating promising response rates in HR-MDS and TP53m AML patients.
The company has also been added to the Russell 2000® and Russell 3000® Indexes, a testament to its progress in the biotechnology sector. Analysts from BTIG and H.C. Wainwright have maintained their Neutral and Buy ratings on Shattuck Labs, respectively, despite the company's recent developments.
BTIG analysts emphasized the need for randomized trial data to fully ascertain the benefits of combining CD47 and CD40 targeting drugs, while H.C. Wainwright reduced its price target for the company.
Shattuck Labs' SL-172154 has shown promising efficacy, potentially leading to significant improvement in patient survival. However, the company's management has pointed out that their trial included a majority of patients with multi-hit TP53 mutations, who generally have a poorer prognosis. The differences in patient populations could be significant in distinguishing SL-172154 from competitors, highlighting the potential for Shattuck Labs' treatment to offer meaningful benefit to patients with AML and HR-MDS.
InvestingPro Insights
In light of the recent developments and analyses, InvestingPro provides additional context for investors considering Shattuck Labs (NASDAQ: STTK). Notably, Shattuck holds more cash than debt on its balance sheet, which could provide some financial stability in the face of market skepticism. Additionally, analysts anticipate a sales growth in the current year, suggesting potential upside despite the challenges in the CD47 pathway. However, it's important to mention that Shattuck is quickly burning through cash, which may raise concerns about long-term sustainability.
From a data perspective, Shattuck Labs has a market cap of $168 million and a very high revenue growth rate of 380.09% over the last twelve months as of Q2 2024. This growth is particularly impressive when considering the quarterly revenue growth of 704.5% for Q2 2024. Despite these growth figures, Shattuck's gross profit margin stands at -1709.92%, indicating significant costs relative to revenues. The company's stock has also experienced volatility with a 58.56% return over the last year, yet it has seen a considerable decline of -51.98% over the last three months.
For investors seeking further insights, InvestingPro has a total of 14 additional InvestingPro Tips available for Shattuck Labs, which can be found at https://www.investing.com/pro/STTK. These tips could provide a more granular perspective on the company's financial health and market performance, aiding in a comprehensive investment decision-making process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.